REG - Physiomics PLC - Publication of Peer Reviewed Article

PhysiomicsAnnouncement

30/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250130:nRSd1908Va&default-theme=true

RNS Number : 1908V  Physiomics PLC  30 January 2025

30 January 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Publication of Peer Reviewed Article

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce the joint online
publication in collaboration with Merck KGaA entitled 'Semi-mechanistic
efficacy model for PARP + ATR inhibitors - application to rucaparib and
talazoparib in combination with gartisertib in breast cancer PDXs' in the
British Journal of Cancer. 

 

The full article can be accessed via the following link:
https://www.nature.com/articles/s41416-024-02935-w
(https://www.nature.com/articles/s41416-024-02935-w)

 

The development of novel effective oncology therapies is very challenging, not
only from a cost perspective, but due to biological factors such as the
emergence of tumour resistance and natural patient-to-patient variations that
influence treatment outcomes. Combination therapies, such as those described
within the paper, can offer a route to overcoming some of these biological
factors and offer more successful treatments.

 

In contrast to developing monotherapies (single drug therapies), the
development of combination therapies creates additional complexity to the
development process as a larger number of possible experimental permutations
need to be explored. If all these permutations were to be explored within
preclinical or clinical settings, the additional cost and time required would
become prohibitive. Physiomics addresses this challenge by offering prediction
services that can be used to understand how these novel therapeutics might
perform in the clinic, enabling a way to focus in on the most effective
experimental permutations to explore, thus accelerating and derisking the drug
development process.

 

In this publication, a mathematical model was developed to explore these
different experimental permutations (doses and schedules) for combination
therapies. Using Physiomics' proprietary 'Virtual Tumour' platform, the model
provided a single, readily interpretable readout of tumour growth inhibition
(TGI). It was also able to assess the variation in treatment response of novel
drug combinations at various doses, and therefore could be used to inform
clinical trial protocol design.

 

This joint publication with Physiomics' long-standing client, Merck KGaA,
demonstrates the impact of the Company's Virtual Tumour platform in supporting
the development of novel Oncology Therapies. Physiomics provides expertise in
using modelling and simulation approaches to accelerate the development of
innovative therapies across a range of therapeutic areas and across the entire
drug development pathway, including early discovery and development.

 

Dr Peter Sargent, CEO, commented:

"We are thrilled to be able to announce this peer-reviewed publication. This
is the second publication we've announced this month, highlighting the utility
and benefit of our Virtual Tumour Model in supporting oncology drug
development. The work described within the publication is testament to our
continued relationship with Merck KGaA, a relationship established over 12
years ago and spanning over 30 contracts."

 

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0) 1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0) 20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBLMPTMTJTBTA